// added the section below on July 01 2024 // till here on July 01 2024

Immune Checkpoint Inhibitors Market

Immune Checkpoint Inhibitors Market Distribution by Key Immune Checkpoint Targets (B7-H3, CD38, CD40, CD47 and ICOS), Target indications, Mechanism of Action, Therapeutic Modalities Used, Type of Therapy, Route of Administration and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Pages
    318

  • View Count
    33164

Immune Checkpoint Inhibitors Market Overview

The immune checkpoint inhibitors market is estimated to be worth $12 billion in 2030 and is expected to grow at CAGR of 15% during the forecast period.

Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2019, in the US alone. The World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years, across the globe. Conventional treatment options, such as chemotherapy, surgery and radiation therapy, are still considered as the current standard of care. However, their efficacy is severely limited, especially when it comes to treating late-stage cancers. Moreover, the non-specific and highly toxic nature of chemotherapy and radiation therapy, are known to have a significant adverse impact on patients’ quality of life.

There are several targeted anti-cancer therapies that are available in the market and many are presently under development. Of these, immune checkpoint therapies have shown a lot of promise as viable and potent treatment options, capable of preventing tumor cells from evading immune surveillance. In 2011, Bristol-Myers Squibb’s Yervoy® (ipilimumab), an anti-CTLA-4 monoclonal antibody, became the first FDA approved immune checkpoint inhibitor which was designed for the treatment of metastatic melanoma. Yervoy®, along with other first generation immune checkpoint inhibitors (targeting PD-1/PD-L1 and CTLA-4), soon demonstrated the ability to substantially prolong the lives of patients suffering from advanced stage tumors. However, despite the success of PD 1 / PD-L1 immune checkpoint inhibitors drugs, there was a notable amount of resistance to treatment reported in certain groups of patients, which compromised the therapeutic potential of this relatively novel class of therapeutics. 

This image highlights the context of Immune Checkpoint Inhibitors Market report. Therapies targeting novel inhibitory and stimulatory immune checkpoints have been shown to possess substantial therapeutic potential both as monotherapies and in combination with other interventions, across multiple disease indications This image provides list of Next-generation Immune Checkpoint Inhibitors and Stimulators. More than 150 industry players across the world are presently engaged in evaluating the potential of nearly 300 next generation immune checkpoint modulators for the treatment of multiple disease indications This image presents current market landscape of Next Generation Immune Checkpoint Inhibitors and Stimulators. The pipeline features a variety of marketed / clinical stage therapies, targeting a number of different types of immune checkpoints and being investigated for administration via different routes

Over the years, significant strides have been made in immune checkpoint modulation research, revealing several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are now being exploited for development of next generation immune checkpoint-based therapies. Moreover, clinical studies of combinatorial immune checkpoint blockade / co-stimulation, involving the newly identified checkpoints and known immune checkpoint inhibitor therapies, have demonstrated the potential to further augment therapeutic benefits. It is worth highlighting that these molecules have also shown to be capable of regulating immune tolerance and preventing / treating autoimmune disorders. Therefore, backed by promising clinical results and expanding applicability of therapies being investigated in late stages of development, the immune checkpoint inhibitors and stimulators market is poised to witness substantial market growth during the forecast period.

Key Companies in Immune Checkpoint Inhibitors Market

Examples of key companies engaged in immune checkpoint inhibitors market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Bristol-Myers Squibb, GlaxoSmithKline, Incyte, Novartis and Trillium Therapeutics. This market report includes an easily searchable excel database of all the companies developing immune checkpoint inhibitors, worldwide.

Recent Developments in Immune Checkpoint Inhibitors Market

Several recent developments have taken place in the field of immune checkpoint inhibitors market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In June 2023, Philogen entered into a clinical trial collaboration with MSD to evaluate Philogen's immunocytokines, including L19IL2, L19TNF and Nidlegy™, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in stage III and IV unresectable melanoma patients who previously failed treatment with checkpoint inhibitors.

Scope of the Immune Checkpoint Inhibitors Market Report

The Immune Checkpoint Inhibitors Market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the immune checkpoint inhibitors market. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in immune checkpoint inhibitors market.

This image provides information about completed, ongoing and planned clinical studies of Next Generation Immune Checkpoint Inhibitors. In the last few years, over 600 clinical studies of various types of immune checkpoint modulation-based therapies, involving nearly 90,000 patients across different centers / hospitals, have been initiated worldwide This image highlights competitive analysis of players engaged in the domain of Immune Checkpoint Inhibitors Market. In the pursuit of obtaining an edge within this emerging and highly competitive market landscape, developers are actively exploring the therapeutic potential of novel immune checkpoints, beyond PD-L1, PD-1 and CTLA-4 This image highlights the initiatives undertaken by big pharma players engaged in Immune Checkpoint Inhibitors Market. Over time, big pharma players have initiated product development programs focused on immune checkpoint modulation for treating various oncological indications, investing significant capital, time and effort

In addition to other elements, the market research report includes:

  • A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory),  type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administration (intravenous, subcutaneous, oral and others), target disease indication, target therapeutic area and type of therapy (monotherapy, combination therapy and both). 
  • A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, type of target, target indication(s), target therapeutic area(s), enrolled patients population and regional distribution.
  • Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.
  • An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects, in the period between 2016 and 2019 (till November), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute center, funding institute center, support period, type of grant application, purpose of grant award, grant mechanism, popular target immune checkpoints, responsible study section, focus area, prominent program officers, and type of recipient organizations. It also features a detailed analysis based on the types of target immune checkpoints and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as grant amount, support period, type of grant application and number of disease indications under investigation.
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (specific to affiliated technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant types of deals. 
  • An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for next generation immune checkpoint therapy development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of grants and number of publications [B] a five-dimensional spider-web analysis, highlighting the most popular immune checkpoint targets.
  • An analysis of the big biopharma players engaged in immune checkpoint inhibitors market, featuring a heat map based on parameters, such as number of therapies under development, target disease indications, partnership activity and target portfolio.

The key objective of immune checkpoint inhibitors market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for immune checkpoint inhibitors market during the forecast period. Based on multiple parameters, such as disease prevalence, anticipated adoption of next generation checkpoint modulator therapies and their likely selling price, we have provided informed estimates on the evolution of the market for the forecast period 2020-2030. The market report also features the likely distribution of the current and forecasted opportunity across [A] different target indications (colorectal cancer, head and neck cancer, lung cancer, lymphoma, melanoma, myeloma, neuroblastoma, primary Sjögren's syndrome and systemic lupus erythematosus / lupus nephritis) [B] key immune checkpoint targets (B7-H3, CD38, CD40, CD47 and ICOS [C] mechanisms of action (inhibitory and costimulatory), [D] therapeutic modalities used (antibody fragment, monoclonal antibody and small molecule), [E] type of therapy (monotherapy, combination therapy and both), [F] route of administration (intravenous, subcutaneous and intracerebroventricular) and [G] key geographical regions (US, EU5, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

This image highlights the partnership activity undertaken by players engaged in Immune Checkpoint Inhibitors Market. The growing interest in this field is also reflected by the 120+ partnerships have been signed in the last two years, involving both international and indigenous stakeholders This image highlights the market segments of Next Generation Immune Checkpoint Modulators Market. The future market, based on the revenue generation potential of marketed and late stage therapies, is anticipated to be distributed across different disease areas, mechanisms and key geographical regions This image provides information on the current and future market trends and potential growth of Next Generation Immune Checkpoint Modulators Market. In the long term, the opportunity is likely to be segmented across diverse therapeutic modalities, immune checkpoint targets and routes of administration

The opinions and insights presented in this market research report were influenced by discussions conducted with multiple stakeholders in immune checkpoint inhibitors market. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are immune checkpoint inhibitors?

Answer: Immune checkpoint inhibitors belong to a novel class of immunotherapies which involves blocking of immune checkpoint proteins from interacting with partner proteins.

Question 2: How big is the immune checkpoint inhibitors market?

Answer: The immune checkpoint inhibitors market size is estimated to be worth $12 billion in 2030.

Question 3: What is the projected market growth of the immune checkpoint inhibitors market?

Answer: The immune checkpoint inhibitors market is expected to grow at compounded annual growth rate (CAGR) of 15% during the forecast period 2020 – 2030.

Question 4: Who are the leading companies in the immune checkpoint inhibitors market?

Answer: Examples of key companies engaged in developing immune checkpoint inhibitors (which have also been profiled in this market report; the complete list of companies is available in the full report) include Bristol-Myers Squibb, GlaxoSmithKline, Incyte, Novartis and Trillium Therapeutics.

Question 5: How many immune checkpoint inhibitors and stimulators are being evaluated in clinical trials?

Answer: Over 250 immune checkpoint inhibitors and stimulators drug candidates are being evaluated in clinical trials.

Question 6: How many partnership deals have been inked between the companies engaged in immune checkpoint inhibitors market?

Answer: Since 2017, more than 140 partnership deals have been inked between the players engaged in immune checkpoint inhibitors market, highlighting the consolidation efforts of stakeholders in the industry.

Question 7: Which region emerged as the hub for companies engaged in the immune checkpoint inhibitors market?

Answer: North America emerged as the hub for companies engaged in the immune checkpoint inhibitors market, with over 70% of the companies established in the region.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com